Lyell Immunopharma, Inc.
LYELHealthcare|Biotechnology|US
$14.86
-0.14 (-0.93%)
DCF Value
$0.36
Tangible Book / Share
$7.89
Cash / Share
$7.25
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07188558 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Large B-cell Lymphoma, Lymphoma, B-Cell | P3 | Recruiting | 400 | RCT, Open-label | rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel |
| NCT05826535 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | P1P2 | Recruiting | 270 | Open-label | Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide |
| NCT05319314 LYL273 for Patients With Relapsed or Refractory mCRC | Colorectal Cancer | P1P2 | Recruiting | 155 | Open-label | LYL273 |
| NCT06153095 A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus, Lupus Nephritis | P1P2 | Withdrawn | — | Open-label | IMPT-514, IMPT-514, IMPT-514 |
| NCT05274451 A Study to Investigate LYL797 in Adults With Solid Tumors | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | P1 | Terminated | 57 | Open-label | LYL797 |
| NCT05573035 A Study to Investigate LYL845 in Adults With Solid Tumors | Melanoma, Non-small Cell Lung Cancer | P1 | Terminated | 39 | Open-label | LYL845 |
| NCT05891197 A Biomarker Screening Protocol for Participants With Solid Tumors | Triple Negative Breast Cancer, Non-small Cell Lung Cancer | Terminated | 10 | — | — |